Advertisement Bioness and OPGA/POINT sign vendor agreement - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Bioness and OPGA/POINT sign vendor agreement

Bioness, a neuromodulation company, and OPGA/POINT Orthotics and Prosthetics, a nationwide network of over 1,300 independently owned and operated orthotic and prosthetic facilities, has signed a vendor agreement to offer Bioness's NESS L300 foot drop system to OPGA/POINT members.

The agreement is intended to increase the availability of the NESS L300 among all OPGA O&P members and to improve the care for persons with foot drop, suffering from neurological disorders including stroke, multiple sclerosis, incomplete spinal cord injury, traumatic brain injury and cerebral palsy.

OPGA members participating in the Bioness program will be trained to evaluate and fit patients, offer the device for home use and refer patients for follow-up therapy to a Bioness-trained rehabilitation facility.

Yitzhak Zilberman, president and CEO of Bioness, said: “We are tremendously excited about the new relationship with OPGA/POINT. It will help expand the availability of the NESS L300 to an enormous number of additional prospective patients who suffer from foot drop, but are not currently undergoing rehabilitation. The NESS L300 has already helped thousands of patients and we believe working with OPGA/POINT will allow us to help many more patients regain mobility.”